Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-15T04:50:43.305Z Has data issue: false hasContentIssue false
  • English
  • Français

Gastrointestinal Selective Capacity of Doripenem, Meropenem, and Imipenem for Carbapenem-Resistant Gram-Negative Bacilli in Treated Patients with Pneumonia

Part of: BARRY FARR AWARD RECIPIENTS

Published online by Cambridge University Press:  02 January 2015

Anucha Apisarnthanarak ,
Pattarachai Kiratisin ,
Piyaporn Apisarnthanarak  and
Linda M. Mundy
Anucha Apisarnthanarak*
Affiliation:
Division of Infectious Diseases, Thammasat University Hospital, Pratumthani, Thailand
Pattarachai Kiratisin
Affiliation:
Department of Microbiology, Siriraj Hospital, Mahidol University, Bangkok, Thailand
Piyaporn Apisarnthanarak
Affiliation:
Department of Radiology, Siriraj Hospital, Mahidol University, Bangkok, Thailand
Linda M. Mundy
Affiliation:
LM Mundy, LLC, Bryn Mawr, Pennsylvania
*
Division of Infectious Diseases, Thammasat University Hospital, Pratumthani, Thailand12120 (anapisarn@yaboo.com)
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Letters to the Editor
Information
Infection Control & Hospital Epidemiology , Volume 32 , Issue 4 , April 2011 , pp. 410 - 411
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2011

References

1. Peleg, AY, Seifert, H, Paterson, DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008;21:538–582.10.1128/CMR.00058-07Google Scholar
2. Paterson, DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006;43(suppl 2):S43–S48.10.1086/504476Google Scholar
3. Fishbain, J, Peleg, AY. Treatment of Acinetobacter infections. Clin Infect Dis 2010;51:79–84.Google Scholar
4. Kang, CI, Kim, SH, Kim, HB, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003;37:745–751.10.1086/377200Google Scholar
5. Micek, ST, Kollef, KE, Reichley, RM, Roubinian, N, Kollef, ME. Health care-associated pneumonia and community acquired pneumonia: a single-center experience. Anhmicrob Agents Chemother 2007;51:3569–3573.Google Scholar
6. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: nineteenth informational supplement. Document M100-S19. Wayne, PA: CLSI, 2009.Google Scholar